(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Germany's far-right AfD tops poll ahead of Merz's conservatives - 2Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- 3Top 10 Arising Advances That Will Shape What's in store
- 4Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 5When a sperm whale gives birth, the mother gets help from her friends
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Heartfelt Objections to Visit with Your Adored One
- Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
- Share your pick for the miniature headphones that you generally suggest!
- A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- The biggest black hole breakthroughs of 2025
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- Figure out How to Score Huge with Open Record Rewards
